

Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential

Horizon Europe

● PENDING

Code

HORIZON-HLTH-2027-01-DISEASE-05

Scope

International

Location

Europe

Curator

Marlene Faria

FINANCIAL DETAILS

Support type

Non-Refundable

Maximum Funding Rate

100%

Budget

44.2M€

Eligible Project Value

9M€ - 11M€

DATES & DEADLINES

Publication Date

Not defined

Opening Date

October 29, 2026

Fase única

February 17, 2027 at 05:00 PM GMT+1

DESCRIPTION

Objectives

This topic aims to advance the development of novel or existing small-molecule antiviral candidates for the prevention and treatment of emerging and re-emerging viral infections. It seeks to expand therapeutic options that can be rapidly deployed during future epidemics or pandemics, strengthen European preparedness and reinforce the EU's leadership in antiviral research and development, in line with the European Medical Countermeasures Strategy. Antibodies and antibody-derived proteins are outside the scope of this topic.

Funding

Funding is provided under a Horizon Europe Research and Innovation Action (RIA). The topic has an indicative budget of €44.2 million, with approximately five projects expected to be funded. The anticipated

EU contribution ranges from €9 million to €11 million per project, although proposals requesting different amounts may be considered where appropriately justified. RIAs may receive funding of up to 100% of eligible costs, in accordance with Horizon Europe rules.

ELIGIBLE EXPENSES

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs
- Personnel
- Research infrastructure
- Equipment
- Consumables
- Travel
- Dissemination activities

ELIGIBILITY

Eligible Sectors

Health & Life Sciences

Application Mode

Consortium / Copromotion

Company Typologies

- Micro
- SME
- Small Mid-Cap
- Mid-Cap
- Large
- Non-business entities of the R&I system (ENESII)
- Private non-profit entities
- Public entities

Action Types

- Research and Innovation Action
- Collaborative Health Research

EU PROGRAMME DETAILS

Call ID	Cluster
HORIZON-HLTH-2027-01-DISEASE-05	Health
Destination	Submission Mode
D3. Tackling diseases and reducing disease burden	Single-stage
EU Contribution	Expected Projects
Around €10,000,000.00 to €11,000,000.00 per project	5
Funding Rate Rule	
Up to 100% of eligible costs for Research and Innovation Actions (RIA)	

OFFICIAL LINKS

Official Regulation

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-DISEASE-05?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-HLTH-2027-01-DISEASE-05&isExactMatch=true&status=31094501,31094502,31094503>

Grantavia page

<https://grantavia.com/en/incentives/development-of-novel-small-molecule-antiviral-therapeutics-for-pathogens-with-epidemic-potential>

Schedule a meeting

<https://calendly.com/sandra-cardoso-epsa/reuniao>